Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study

Pleural mesothelioma (PM) is an aggressive tumor with few therapeutic options. Although patients with epithelioid PM (ePM) survive longer than non-epithelioid PM (non-ePM), heterogeneity of tumor response in ePM is observed. The role of the tumor immune microenvironment (TIME) in the development and...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-05, Vol.23 (10), p.5786
Main Authors: Mannarino, Laura, Paracchini, Lara, Pezzuto, Federica, Olteanu, Gheorghe Emilian, Moracci, Laura, Vedovelli, Luca, De Simone, Irene, Bosetti, Cristina, Lupi, Monica, Amodeo, Rosy, Inglesi, Alessia, Callari, Maurizio, Penpa, Serena, Libener, Roberta, Delfanti, Sara, De Angelis, Antonina, Muzio, Alberto, Zucali, Paolo Andrea, Allavena, Paola, Ceresoli, Giovanni Luca, Marchini, Sergio, Calabrese, Fiorella, D'Incalci, Maurizio, Grosso, Federica
Format: Article
Language:English
Subjects:
Antigens
B cells
Cancer therapies
CD20
Chemotherapy
Heterogeneity
Humans
Immune system
Inflammation
long survivors
Lymphocytes
Lymphocytes B
Medical prognosis
Mesothelioma
Mesothelioma - genetics
Mesothelioma, Malignant
Metastases
Microenvironments
Neutrophils
Patients
Pleural Neoplasms - genetics
Regulation
Survival
Survivors
tertiary lymphoid structures
Tertiary Lymphoid Structures - pathology
transcriptomics
Tumor Microenvironment - genetics
Tumor-infiltrating lymphocytes
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pleural mesothelioma (PM) is an aggressive tumor with few therapeutic options. Although patients with epithelioid PM (ePM) survive longer than non-epithelioid PM (non-ePM), heterogeneity of tumor response in ePM is observed. The role of the tumor immune microenvironment (TIME) in the development and progression of PM is currently considered a promising biomarker. A few studies have used high-throughput technologies correlated with TIME evaluation and morphologic and clinical data. This study aimed to identify different morphological, immunohistochemical, and transcriptional profiles that could potentially predict the outcome. A retrospective multicenter cohort of 129 chemonaive PM patients was recruited. Tissue slides were reviewed by dedicated pathologists for histotype classification and immunophenotype of tumor-infiltrating lymphocytes (TILs) and lymphoid aggregates or tertiary lymphoid structures (TLS). ePM (n = 99) survivors were further classified into long (>36 months) or short (
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms23105786